Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $8.86

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $8.86.

Several research analysts have weighed in on VOR shares. HC Wainwright lowered their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Stifel Nicolaus lowered their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Oppenheimer reiterated an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Finally, Wedbush reissued an "outperform" rating and issued a $7.00 price objective on shares of Vor Biopharma in a research note on Thursday, March 20th.

Vor Biopharma Price Performance

Shares of NYSE:VOR traded up $0.01 during trading on Monday, reaching $0.74. 25,441 shares of the stock were exchanged, compared to its average volume of 586,436. Vor Biopharma has a 1-year low of $0.49 and a 1-year high of $1.87. The stock has a fifty day moving average of $0.85 and a two-hundred day moving average of $0.98. The firm has a market cap of $92.27 million, a price-to-earnings ratio of -0.45 and a beta of -0.21.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently modified their holdings of VOR. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Vor Biopharma during the fourth quarter valued at approximately $33,000. Money Concepts Capital Corp increased its position in shares of Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Vor Biopharma during the 4th quarter worth $60,000. XTX Topco Ltd purchased a new position in shares of Vor Biopharma in the 4th quarter worth about $80,000. Finally, Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the 4th quarter worth about $102,000. Institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.